Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease
Objective To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves’ disease (GD). Methods After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US...
Gespeichert in:
| Veröffentlicht in: | European radiology 2019-12, Vol.29 (12), p.6690-6698 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6698 |
|---|---|
| container_issue | 12 |
| container_start_page | 6690 |
| container_title | European radiology |
| container_volume | 29 |
| creator | Lang, Brian Hung-Hin Woo, Yu-Cho Chiu, Keith Wan-Hang |
| description | Objective
To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves’ disease (GD).
Methods
After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US-guided HIFU ablation from 2016 to 2017 were retrospectively analyzed. Altogether, 75 patients received HIFU ablation of the central portion of the right and left thyroid lobes with areas near the trachea–esophageal groove and common carotid artery un-ablated. They were followed for 24 months or longer. Baseline thyrotropin (TSH), free T4, anti-thyroid autoantibodies, and TSH receptor (TSHR) antibody were checked. Primary outcome was the 24-month relapse rate. Relapse referred to hyperthyroidism (free T4 (FT4) > 23 pmol/L) afterwards. Variables associated with relapse were analyzed by binary logistic regression.
Results
The cohort comprised mostly females (84.0%) with a mean age of 42.05 ± 10.74 years. The 24-month relapse rate was 41.3% with 31 patients suffering a relapse. No patient suffered from hypothyroidism. Three patients (4.0%) suffered from temporary vocal cord palsy but these injuries recovered spontaneously after 2 months. In univariate analysis, higher daily dose of carbimazole (OR = 1.125, 95% CI = 1.023–1.237,
p
= 0.015) and higher baseline TSHR level (OR = 1.085, 95% CI = 1.022–1.152,
p
= 0.007) were significant factors for disease relapse. In the multivariate analysis, higher baseline TSHR level was a significant independent factor for disease relapse within 24 months (OR = 1.079, 95% CI = 1.014–1.148,
p
= 0.016).
Conclusions
US-guided HIFU of the thyroid gland was a safe and relatively efficacious treatment in the longer term for patients with persistent or relapsed GD.
Key Points
•
US-guided HIFU ablation is relatively efficacious in the longer term.
•
US-guided HIFU ablation of the thyroid is safe.
•
Higher TSHR level may lead to higher disease relapse after treatment
. |
| doi_str_mv | 10.1007/s00330-019-06303-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242811205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2241833156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-9125edf6ccdac469843c5f9085178ce1e95f5564a92a32dcdac409a170131a823</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS1ERIbAD7BAltiEhZOy3Q97iSLykCKxSdYt466eOOq2B5cbNDvEX_B7fAk9mQASi6ysks-9Zfkw9kbCiQRoTwlAaxAgrYBGgxbmGVvJSishwVTP2QqsNqK1tjpkL4nuAcDKqn3BDrVUYBulVuzHzbcktugyT3PxaULiaeAU4npEQUgUUuR3YX0nQiwYKZQtH5KfCXs-jyU7SnPs-fHl1fnte14yujJhLDxEvsFMgcpuSplnHN1ml7rI7ivSr-8_eR8IHeErdjC4kfD143nEbs8_3pxdiutPF1dnH66F121dhJWqxn5ovO-drxprKu3rwYKpZWs8SrT1UNdN5axyWvUPFFgnW5BaOqP0ETve925y-jIjlW4K5HEcXcQ0U6dUpYxcfqZe0Hf_ofdpznF53Y6SRmtZNwul9pTPiSjj0G1ymFzedhK6naFub6hbDHUPhjqzhN4-Vs-fJ-z_Rv4oWQC9B2i5imvM_3Y_Ufsbn1Sdpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241833156</pqid></control><display><type>article</type><title>Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lang, Brian Hung-Hin ; Woo, Yu-Cho ; Chiu, Keith Wan-Hang</creator><creatorcontrib>Lang, Brian Hung-Hin ; Woo, Yu-Cho ; Chiu, Keith Wan-Hang</creatorcontrib><description>Objective
To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves’ disease (GD).
Methods
After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US-guided HIFU ablation from 2016 to 2017 were retrospectively analyzed. Altogether, 75 patients received HIFU ablation of the central portion of the right and left thyroid lobes with areas near the trachea–esophageal groove and common carotid artery un-ablated. They were followed for 24 months or longer. Baseline thyrotropin (TSH), free T4, anti-thyroid autoantibodies, and TSH receptor (TSHR) antibody were checked. Primary outcome was the 24-month relapse rate. Relapse referred to hyperthyroidism (free T4 (FT4) > 23 pmol/L) afterwards. Variables associated with relapse were analyzed by binary logistic regression.
Results
The cohort comprised mostly females (84.0%) with a mean age of 42.05 ± 10.74 years. The 24-month relapse rate was 41.3% with 31 patients suffering a relapse. No patient suffered from hypothyroidism. Three patients (4.0%) suffered from temporary vocal cord palsy but these injuries recovered spontaneously after 2 months. In univariate analysis, higher daily dose of carbimazole (OR = 1.125, 95% CI = 1.023–1.237,
p
= 0.015) and higher baseline TSHR level (OR = 1.085, 95% CI = 1.022–1.152,
p
= 0.007) were significant factors for disease relapse. In the multivariate analysis, higher baseline TSHR level was a significant independent factor for disease relapse within 24 months (OR = 1.079, 95% CI = 1.014–1.148,
p
= 0.016).
Conclusions
US-guided HIFU of the thyroid gland was a safe and relatively efficacious treatment in the longer term for patients with persistent or relapsed GD.
Key Points
•
US-guided HIFU ablation is relatively efficacious in the longer term.
•
US-guided HIFU ablation of the thyroid is safe.
•
Higher TSHR level may lead to higher disease relapse after treatment
.</description><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-019-06303-8</identifier><identifier>PMID: 31209622</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Ablation ; Adult ; Antibodies ; Autoantibodies ; Carotid artery ; Chronic Disease ; Diagnostic Radiology ; Esophagus ; Female ; Females ; Follow-Up Studies ; Graves Disease - surgery ; Graves' disease ; Grooves ; High-Intensity Focused Ultrasound Ablation - methods ; Humans ; Hyperthyroidism ; Hypothyroidism ; Imaging ; Immunoglobulins, Thyroid-Stimulating ; Injury analysis ; Internal Medicine ; Interventional Radiology ; Laboratory tests ; Male ; Medical treatment ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Neuroradiology ; Paralysis ; Radiology ; Recurrence ; Regression analysis ; Retrospective Studies ; Thyroid ; Thyroid gland ; Thyroid Gland - surgery ; Thyroid-stimulating hormone ; Thyroid-stimulating hormone receptors ; Thyroxine ; Trachea ; Treatment Outcome ; Ultrasonic imaging ; Ultrasound ; Vocal Cord Paralysis</subject><ispartof>European radiology, 2019-12, Vol.29 (12), p.6690-6698</ispartof><rights>European Society of Radiology 2019</rights><rights>European Radiology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-9125edf6ccdac469843c5f9085178ce1e95f5564a92a32dcdac409a170131a823</citedby><cites>FETCH-LOGICAL-c375t-9125edf6ccdac469843c5f9085178ce1e95f5564a92a32dcdac409a170131a823</cites><orcidid>0000-0002-9362-0086</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00330-019-06303-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00330-019-06303-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31209622$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, Brian Hung-Hin</creatorcontrib><creatorcontrib>Woo, Yu-Cho</creatorcontrib><creatorcontrib>Chiu, Keith Wan-Hang</creatorcontrib><title>Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><addtitle>Eur Radiol</addtitle><description>Objective
To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves’ disease (GD).
Methods
After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US-guided HIFU ablation from 2016 to 2017 were retrospectively analyzed. Altogether, 75 patients received HIFU ablation of the central portion of the right and left thyroid lobes with areas near the trachea–esophageal groove and common carotid artery un-ablated. They were followed for 24 months or longer. Baseline thyrotropin (TSH), free T4, anti-thyroid autoantibodies, and TSH receptor (TSHR) antibody were checked. Primary outcome was the 24-month relapse rate. Relapse referred to hyperthyroidism (free T4 (FT4) > 23 pmol/L) afterwards. Variables associated with relapse were analyzed by binary logistic regression.
Results
The cohort comprised mostly females (84.0%) with a mean age of 42.05 ± 10.74 years. The 24-month relapse rate was 41.3% with 31 patients suffering a relapse. No patient suffered from hypothyroidism. Three patients (4.0%) suffered from temporary vocal cord palsy but these injuries recovered spontaneously after 2 months. In univariate analysis, higher daily dose of carbimazole (OR = 1.125, 95% CI = 1.023–1.237,
p
= 0.015) and higher baseline TSHR level (OR = 1.085, 95% CI = 1.022–1.152,
p
= 0.007) were significant factors for disease relapse. In the multivariate analysis, higher baseline TSHR level was a significant independent factor for disease relapse within 24 months (OR = 1.079, 95% CI = 1.014–1.148,
p
= 0.016).
Conclusions
US-guided HIFU of the thyroid gland was a safe and relatively efficacious treatment in the longer term for patients with persistent or relapsed GD.
Key Points
•
US-guided HIFU ablation is relatively efficacious in the longer term.
•
US-guided HIFU ablation of the thyroid is safe.
•
Higher TSHR level may lead to higher disease relapse after treatment
.</description><subject>Ablation</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Carotid artery</subject><subject>Chronic Disease</subject><subject>Diagnostic Radiology</subject><subject>Esophagus</subject><subject>Female</subject><subject>Females</subject><subject>Follow-Up Studies</subject><subject>Graves Disease - surgery</subject><subject>Graves' disease</subject><subject>Grooves</subject><subject>High-Intensity Focused Ultrasound Ablation - methods</subject><subject>Humans</subject><subject>Hyperthyroidism</subject><subject>Hypothyroidism</subject><subject>Imaging</subject><subject>Immunoglobulins, Thyroid-Stimulating</subject><subject>Injury analysis</subject><subject>Internal Medicine</subject><subject>Interventional Radiology</subject><subject>Laboratory tests</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Neuroradiology</subject><subject>Paralysis</subject><subject>Radiology</subject><subject>Recurrence</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><subject>Thyroid Gland - surgery</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroid-stimulating hormone receptors</subject><subject>Thyroxine</subject><subject>Trachea</subject><subject>Treatment Outcome</subject><subject>Ultrasonic imaging</subject><subject>Ultrasound</subject><subject>Vocal Cord Paralysis</subject><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kctuFDEQRS1ERIbAD7BAltiEhZOy3Q97iSLykCKxSdYt466eOOq2B5cbNDvEX_B7fAk9mQASi6ysks-9Zfkw9kbCiQRoTwlAaxAgrYBGgxbmGVvJSishwVTP2QqsNqK1tjpkL4nuAcDKqn3BDrVUYBulVuzHzbcktugyT3PxaULiaeAU4npEQUgUUuR3YX0nQiwYKZQtH5KfCXs-jyU7SnPs-fHl1fnte14yujJhLDxEvsFMgcpuSplnHN1ml7rI7ivSr-8_eR8IHeErdjC4kfD143nEbs8_3pxdiutPF1dnH66F121dhJWqxn5ovO-drxprKu3rwYKpZWs8SrT1UNdN5axyWvUPFFgnW5BaOqP0ETve925y-jIjlW4K5HEcXcQ0U6dUpYxcfqZe0Hf_ofdpznF53Y6SRmtZNwul9pTPiSjj0G1ymFzedhK6naFub6hbDHUPhjqzhN4-Vs-fJ-z_Rv4oWQC9B2i5imvM_3Y_Ufsbn1Sdpg</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Lang, Brian Hung-Hin</creator><creator>Woo, Yu-Cho</creator><creator>Chiu, Keith Wan-Hang</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9362-0086</orcidid></search><sort><creationdate>20191201</creationdate><title>Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease</title><author>Lang, Brian Hung-Hin ; Woo, Yu-Cho ; Chiu, Keith Wan-Hang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-9125edf6ccdac469843c5f9085178ce1e95f5564a92a32dcdac409a170131a823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ablation</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Carotid artery</topic><topic>Chronic Disease</topic><topic>Diagnostic Radiology</topic><topic>Esophagus</topic><topic>Female</topic><topic>Females</topic><topic>Follow-Up Studies</topic><topic>Graves Disease - surgery</topic><topic>Graves' disease</topic><topic>Grooves</topic><topic>High-Intensity Focused Ultrasound Ablation - methods</topic><topic>Humans</topic><topic>Hyperthyroidism</topic><topic>Hypothyroidism</topic><topic>Imaging</topic><topic>Immunoglobulins, Thyroid-Stimulating</topic><topic>Injury analysis</topic><topic>Internal Medicine</topic><topic>Interventional Radiology</topic><topic>Laboratory tests</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Neuroradiology</topic><topic>Paralysis</topic><topic>Radiology</topic><topic>Recurrence</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><topic>Thyroid Gland - surgery</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroid-stimulating hormone receptors</topic><topic>Thyroxine</topic><topic>Trachea</topic><topic>Treatment Outcome</topic><topic>Ultrasonic imaging</topic><topic>Ultrasound</topic><topic>Vocal Cord Paralysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, Brian Hung-Hin</creatorcontrib><creatorcontrib>Woo, Yu-Cho</creatorcontrib><creatorcontrib>Chiu, Keith Wan-Hang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, Brian Hung-Hin</au><au>Woo, Yu-Cho</au><au>Chiu, Keith Wan-Hang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease</atitle><jtitle>European radiology</jtitle><stitle>Eur Radiol</stitle><addtitle>Eur Radiol</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>29</volume><issue>12</issue><spage>6690</spage><epage>6698</epage><pages>6690-6698</pages><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Objective
To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves’ disease (GD).
Methods
After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US-guided HIFU ablation from 2016 to 2017 were retrospectively analyzed. Altogether, 75 patients received HIFU ablation of the central portion of the right and left thyroid lobes with areas near the trachea–esophageal groove and common carotid artery un-ablated. They were followed for 24 months or longer. Baseline thyrotropin (TSH), free T4, anti-thyroid autoantibodies, and TSH receptor (TSHR) antibody were checked. Primary outcome was the 24-month relapse rate. Relapse referred to hyperthyroidism (free T4 (FT4) > 23 pmol/L) afterwards. Variables associated with relapse were analyzed by binary logistic regression.
Results
The cohort comprised mostly females (84.0%) with a mean age of 42.05 ± 10.74 years. The 24-month relapse rate was 41.3% with 31 patients suffering a relapse. No patient suffered from hypothyroidism. Three patients (4.0%) suffered from temporary vocal cord palsy but these injuries recovered spontaneously after 2 months. In univariate analysis, higher daily dose of carbimazole (OR = 1.125, 95% CI = 1.023–1.237,
p
= 0.015) and higher baseline TSHR level (OR = 1.085, 95% CI = 1.022–1.152,
p
= 0.007) were significant factors for disease relapse. In the multivariate analysis, higher baseline TSHR level was a significant independent factor for disease relapse within 24 months (OR = 1.079, 95% CI = 1.014–1.148,
p
= 0.016).
Conclusions
US-guided HIFU of the thyroid gland was a safe and relatively efficacious treatment in the longer term for patients with persistent or relapsed GD.
Key Points
•
US-guided HIFU ablation is relatively efficacious in the longer term.
•
US-guided HIFU ablation of the thyroid is safe.
•
Higher TSHR level may lead to higher disease relapse after treatment
.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31209622</pmid><doi>10.1007/s00330-019-06303-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9362-0086</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0938-7994 |
| ispartof | European radiology, 2019-12, Vol.29 (12), p.6690-6698 |
| issn | 0938-7994 1432-1084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2242811205 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Ablation Adult Antibodies Autoantibodies Carotid artery Chronic Disease Diagnostic Radiology Esophagus Female Females Follow-Up Studies Graves Disease - surgery Graves' disease Grooves High-Intensity Focused Ultrasound Ablation - methods Humans Hyperthyroidism Hypothyroidism Imaging Immunoglobulins, Thyroid-Stimulating Injury analysis Internal Medicine Interventional Radiology Laboratory tests Male Medical treatment Medicine Medicine & Public Health Multivariate analysis Neuroradiology Paralysis Radiology Recurrence Regression analysis Retrospective Studies Thyroid Thyroid gland Thyroid Gland - surgery Thyroid-stimulating hormone Thyroid-stimulating hormone receptors Thyroxine Trachea Treatment Outcome Ultrasonic imaging Ultrasound Vocal Cord Paralysis |
| title | Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves’ disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A07%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two-year%20outcomes%20of%20single-session%20high-intensity%20focused%20ultrasound%20(HIFU)%20treatment%20in%20persistent%20or%20relapsed%20Graves%E2%80%99%20disease&rft.jtitle=European%20radiology&rft.au=Lang,%20Brian%20Hung-Hin&rft.date=2019-12-01&rft.volume=29&rft.issue=12&rft.spage=6690&rft.epage=6698&rft.pages=6690-6698&rft.issn=0938-7994&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-019-06303-8&rft_dat=%3Cproquest_cross%3E2241833156%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2241833156&rft_id=info:pmid/31209622&rfr_iscdi=true |